Month: August 2020
-
Food Allergy Biotech Acquired for $2.6B
Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion.
-
Covid-19 Vaccines, Therapies – 31 August 2020
The European Commission announced today a contribution of €400 million ($US 477 million) to the COVID-19 Vaccine Global Access, or Covax, consortium.
-
Does Ad Tech Explain The Recession Recovery?
Technology seems to be allowing the factors of production to slosh about at will, without much friction.
-
Taking a Break
We’re taking this week off at Science & Enterprise, to concentrate on a big photography project, and will return on 31 August.
-
Infographic – Biotech Index Cruising in High Range
Looking back to May shows that NBI has largely settled in to the 4,000 to 4,500 range, without volatile swings in either direction.
-
Engineered Mosquitoes Approved for Disease Control
In an apparent end to a long-running dispute, authorities in the Florida Keys approved a field trial of engineered mosquitoes to control tropical diseases.
-
Space Mission Testing Sail to Return Launch Vehicles
A space mission in November will test a device that works like a sail to bring back launch vehicles faster, designed by university aerospace lab and start-up company.
-
DoD Funding Variable Covid-19 Vaccine Technology
The U.S. Department of Defense is funding work on a Covid-19 vaccine platform that can adjust its formula to protect against future mutations in the virus.
-
Vaccine Blocks Covid-19 Infections in Animal Tests
An experimental vaccine shows in challenge tests with monkeys it protects against Covid-19 infections in nose, throat, and airways.
-
Do The Economics Of Online Retail Make Sense?
Commentators that have done in-depth analyses on the likely future performance of the sector also seem to agree that things will get better.